Lung Disease Clinical Trial
Official title:
A Phase 2, Multicenter, Open-label Study to Measure the Safety of Extending Preservation and Assessment Time of Donor Lungs Using Normothermic Ex Vivo Lung Perfusion and Ventilation (EVLP) as Administered by the SPONSOR Using the Toronto EVLP System™
This is a safety study to compare the safety of receiving a lung treated with the Toronto EVLP System™ by SPONSOR in SPONSOR's dedicated facility against standard lung transplantation.
Human donor lungs allocated to a participating study transplant center (Study Center) for a specific recipient and meeting study EVLP donor lung inclusion/exclusion criteria will be assessed by SPONSOR for inclusion into the study. Upon retrieval, donor lung(s) will be packaged and transported on ice to the SPONSOR's EVLP facility in Silver Spring, Maryland, no differently than when lungs are recovered, packaged, and transported to any transplant center for implantation. The EVLP procedure will be performed by Certified Ex Vivo Lung Specialists using the Toronto EVLP System™ for up to 6 hours, collecting and relaying lung function assessment data hourly or as requested by the Study Center transplant surgeon. Additionally, the Study Center surgeon will have the capability to evaluate lung function data and monitor the procedure remotely through a dedicated video link. Upon acceptance of an EVLP donor lung by the Study Center, the single lung or lung block is cooled down by the Toronto EVLP System™ to 10 degrees C. Thereafter, perfusion and ventilation are stopped and the lung is prepared for hypothermic storage and transport to the accepting Study Center. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02217423 -
Abdominal Circumference and Cardiorespiratory Repercussions in Patients Submitted to Physical Therapy
|
N/A | |
Withdrawn |
NCT02253667 -
Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients
|
N/A | |
Completed |
NCT01679301 -
Evaluation of Sleep Mode Within the Respironics SimplyGo Portable Oxygen Concentrator
|
N/A | |
Completed |
NCT02345135 -
Susceptibility to Infections in Ataxia Telangiectasia
|
N/A | |
Terminated |
NCT00966823 -
Fetal Tracheal Balloon Study in Diaphragmatic Hernia
|
Phase 2 | |
Completed |
NCT00139152 -
Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair
|
Phase 4 | |
Completed |
NCT00052052 -
An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
Completed |
NCT00013949 -
Cardiovascular Vulnerability to Particulate Exposure
|
N/A | |
Recruiting |
NCT02963467 -
Effect of Smoking on Ventilation-Perfusion Ratio
|
N/A | |
Recruiting |
NCT02965300 -
The Value of VOCs Analysis in Exhaled Breath for Pulmonary Benign and Malignant Lesion Diagnosis
|
N/A | |
Enrolling by invitation |
NCT02946658 -
Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT02913365 -
Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis
|
N/A | |
Completed |
NCT01735526 -
Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide After Hematopoietic Stem-cell Transplantation
|
N/A | |
Completed |
NCT01952002 -
Clinical Safety for the Inspiratory Muscle Training
|
N/A | |
Recruiting |
NCT01450644 -
Evaluation of the Hospital2Home Palliative Care Service for Patients With Advanced Progressive Lung Disease
|
Phase 2 | |
Completed |
NCT01153321 -
Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Completed |
NCT01215279 -
AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)
|
Phase 2 | |
Completed |
NCT00837681 -
Pulmonary Complications of Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT02055222 -
Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
|
||
Completed |
NCT01222442 -
To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart
|
Phase 1 |